Company Overview of Palatin Technologies, Inc.
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the United States. The company’s principal product is Bremelanotide, an as needed subcutaneous injectable peptide melanocortin receptor agonist, which is in the Phase III clinical studies for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). Its drug development programs also include Melanocortin receptor-4 (MC4r) peptides and small molecule agonists that are under the preclinical trials for the treatment of conditions responsive to MC4r activation, including female sexual dysfunction, HSDD, erectile dysf...
Cedar Brook Corporate Center
4B Cedar Brook Drive
Cranbury, NJ 08512
Founded in 1986
Key Executives for Palatin Technologies, Inc.
Co-Founder, President, CEO & Director
Total Annual Compensation: $577.4K
Executive VP, CFO, COO, Treasurer & Secretary
Total Annual Compensation: $527.2K
Compensation as of Fiscal Year 2016.
Palatin Technologies, Inc. Key Developments
Palatin Technologies, Inc. Appoints Dr. Anthony M. Manning, Ph.D. to Board of Directors
Sep 12 17
Palatin Technologies, Inc. announced that Anthony M. Manning, Ph.D. was appointed to Palatin's Board of Directors on September 7, 2017. Dr. Manning currently serves as the Senior Vice President of Research at Momenta Pharmaceuticals, Inc, Cambridge, MA. Dr. Manning is responsible for research and the discovery of novel products as the Senior Vice President of Research at Momenta Pharmaceuticals, Inc. Since joining Momenta, his team has advanced three novel autoimmune drugs into development. Prior to Momenta, Dr. Manning was Vice President and Head of Immunology Research for Biogen Idec, Inc. Before that, he was Vice President and Global Head of Inflammation, Autoimmunity and Transplantation Research at Roche Pharmaceuticals.
Palatin Technologies Announces Sign Licensing Agreement with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. Rights to Bremelanotide
Sep 6 17
Palatin Technologies, Inc. announced that it has entered into a collaboration and license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. for exclusive rights to develop and commercialize bremelanotide for female sexual dysfunction (FSD) indications in the territories of mainland China, Taiwan, Hong Kong S.A.R. and Macau S.A.R. Bremelanotide is an investigational product designed for on-demand treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Under the terms of the agreement, Palatin will receive an upfront payment of $5.0 million and a $7.5 million milestone based on regulatory approval in China. Palatin has the potential to receive up to $92.5 million in sales related milestones and high single-digit to low double-digit royalties on net sales in the licensed territory. All development, regulatory, sales, marketing, and commercial activities and associated costs in the licensed territory will be the sole responsibility of Fosun Pharma.
Palatin Technologies, Inc. Presents at Rodman & Renshaw 19th Annual Global Investment Conference, Sep-12-2017 08:20 AM
Sep 6 17
Palatin Technologies, Inc. Presents at Rodman & Renshaw 19th Annual Global Investment Conference, Sep-12-2017 08:20 AM. Venue: Lotte New York Palace Hotel, 55 Madison Ave, New York, New York, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|